KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Pfizer (PFE) over the last 16 years, with Q3 2025 value amounting to $19.5 billion.

  • Pfizer's Other Accumulated Expenses fell 204.85% to $19.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 billion, marking a year-over-year decrease of 204.85%. This contributed to the annual value of $19.7 billion for FY2024, which is 397.82% down from last year.
  • Per Pfizer's latest filing, its Other Accumulated Expenses stood at $19.5 billion for Q3 2025, which was down 204.85% from $18.6 billion recorded in Q2 2025.
  • Pfizer's 5-year Other Accumulated Expenses high stood at $24.9 billion for Q4 2021, and its period low was $12.8 billion during Q2 2021.
  • Its 5-year average for Other Accumulated Expenses is $19.6 billion, with a median of $19.7 billion in 2024.
  • As far as peak fluctuations go, Pfizer's Other Accumulated Expenses soared by 11571.66% in 2021, and later tumbled by 3248.66% in 2023.
  • Over the past 5 years, Pfizer's Other Accumulated Expenses (Quarter) stood at $24.9 billion in 2021, then decreased by 9.51% to $22.6 billion in 2022, then dropped by 9.0% to $20.5 billion in 2023, then fell by 3.98% to $19.7 billion in 2024, then decreased by 1.07% to $19.5 billion in 2025.
  • Its Other Accumulated Expenses was $19.5 billion in Q3 2025, compared to $18.6 billion in Q2 2025 and $20.0 billion in Q1 2025.